| [1] |
QI Linling, LIU Shourong.
Research progress of tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 578-582.
|
| [2] |
TAO Chengjing, LIU Shourong, CHENG Xiaoxian, HU Jiannv, BAI Xiuli, ZHANG Suying, ZHAO Chun, ZUO Zhongbao.
Effects of different postpartum withdrawal time of tenofovir on hepatitis B virus markers, virology and biochemical indexes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1146-1152.
|
| [3] |
CHEN Yonghua, CAO Qunfen, HONG Qiongyi, WANG Shumin.
Effect of tenofovir disoproxil fumarate on serum FGF-23，β2-MG，Cys-C and RBP level in patients with chronic hepatitis B
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 799-804.
|
| [4] |
LUAN Ling, ZHANG Jing-Liang.
Clinical efficacy of atomolan in treatment of the patients with virus hepatitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(3): 351-353.
|
| [5] |
ZHANG Jing-Liang, JIA Chuan-Chun, LUAN Ling.
Comparison of the efficacy between stronger Neo-Minophagen C(SNMC) and caryophyllin in treatment of patients with chronic hepatitis B
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(2): 207-209.
|
| [6] |
YU Yong-Sheng, CHEN You-Hua.
Recent advances in genetic therapy for anti-hepatitis B virus
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(6): 574-576.
|
| [7] |
LI Yi-Ling, WANG Feng-Ha, LI Qing-Yang.
Effets of interferon α-2b on serum hpaluronic acid in patients with hypatitis B and hypatitis C
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(1): 80-80.
|
| [8] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2001, 6(4): 370-370.
|
| [9] |
YU Yong-Sheng, CHEN You-Hua.
Immune modulation of anti-HBV iRNA from different sources in patients with chronic hepatitis B
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2000, 5(3): 210-212.
|
| [10] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1997, 2(4): 313-313.
|
| [11] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1997, 2(3): 231-232.
|
| [12] |
WANG Chun-Ge, ZHANG Yi.
Therapeutic progress on the treatment of hepatitis B recurrence after liver transplantation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(3): 283-285.
|
| [13] |
PENG Guan-qing, ZHANG Chang, LIU Xue-feng.
Clinical character of patients relapsed after withdrawal with lamivudine therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1166-1169.
|
| [14] |
LIU Xue-ni, PAN Qing-chun, ZANG Guo-qing, YU Yong-sheng.
Structure of hepatitis B virus core protein and disablement in the hepatitis B antiviral therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1170-1173.
|
| [15] |
ZHU Yue-ke, DUAN Zhong-ping, WANG Bao-en, SHAN Jing, CHEN Yu, HAN Da-kang, ZHAO Jun.
Therapeutic effects of silybin-phosphatidylcholine compound on patients with chronic hepatitis B
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(12): 1392-1394.
|
